The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Thrombolysis is a method of dissolving the blood clot that is the cause of the majority of strokes in Australia. The first major trial to demonstrate benefit for this treatment was published some 11 years ago but treatment has not been widely implemented across Australia because of the difficulties in giving treatment within the very tight time window for which treatment is currently approved (patients must get to hospital, be scanned and start treatment within 3 hours of the onset of the stroke ....Thrombolysis is a method of dissolving the blood clot that is the cause of the majority of strokes in Australia. The first major trial to demonstrate benefit for this treatment was published some 11 years ago but treatment has not been widely implemented across Australia because of the difficulties in giving treatment within the very tight time window for which treatment is currently approved (patients must get to hospital, be scanned and start treatment within 3 hours of the onset of the stroke). Other factors which have limited implementation of treatment in Australia are continued debate over the trial data for this treatment as only one of the 5 major trials was positive. In addition, virtually no patients aged over 80 years old were included in the previous trials, and as this age group represents about a third of all stroke in Australia, new data in this age group is required. As a result of the difficulty in giving a treatment within such a tight time window and the ongoing debate about the trial data, few Australians are currently treated and thus the public health impact is negligible. In to change clinical practice, we need reliable data from a large convincing further trial of thrombolysis with the more realistic time window of 6 hours. The Third International Stroke Trial (IST-3) is a large international collaborative effort to determine whether thrombolysis treatment offered to a wider range of patients up to 6 hours from stroke onset results in an increase in long-term independent survival. Data from such a trial is most likely to change clinical practice and lead to an important public health benefit.Read moreRead less
Centre For Research Excellence In Stroke Rehabilitation And Brain Recovery
Funder
National Health and Medical Research Council
Funding Amount
$2,595,746.00
Summary
The Centre of Research Excellence in Stroke Rehabilitation and Brain Recovery will transform the stroke research and practice landscape in Australia, and accelerate the development of new interventions strongly supported by neuroscience. This unique collaboration will improve patient selection and rehabilitation research methods, create a training culture for the next generation of rehabilitation researchers and effectively implement proven cost effective interventions for Australians.
REVERSIBLE AND IRREVERSIBLE TNF-MEDIATED COGNITIVE DECLINE
Funder
National Health and Medical Research Council
Funding Amount
$444,460.00
Summary
This proposal seeks to clarify the neuronal mechanisms underlying the inflammatory processing leading to cognitive decline. Furthermore, the research project identifies anti-inflammatory treatment options aiming at improved cognitive performance in people at risk for or suffering from cognitive impairment of neuropsychiatric disorders such as dementia and depression.
Patterns Of Care And Outcomes For Subarachnoid Haemorrhage: A Data Linkage Study
Funder
National Health and Medical Research Council
Funding Amount
$125,625.00
Summary
As many as 30% of people with subarachnoid haemorrahge (SAH) die within 90 days. Survivors are often left disabled. Death rates appear to be decreasing. Identifying health service variables that impact positively on survival has the potential to inform health policy and practice. We will describe variations in mortality, hospital re-admission and patterns of care. The study will observe the uptake of new SAH management including new neurosurgical techniques.
Translating Epilepsy Research Into Clinical Practice
Funder
National Health and Medical Research Council
Funding Amount
$188,226.00
Summary
We aim to turn laboratory science into real improvements in the health of people with epilepsy. Firstly, a rise in the acidity of the blood from breathing less and a rise in carbon dioxide, may contribute to seizures finishing. We aim to develop a safe, rapid, non-sedating way to treat seizures using a small amount of carbon dioxide in oxygen. Secondly, inherited problems with transporting sugar from the blood to the brain are increasingly recognised as a cause of epilepsy. We will develop a nat ....We aim to turn laboratory science into real improvements in the health of people with epilepsy. Firstly, a rise in the acidity of the blood from breathing less and a rise in carbon dioxide, may contribute to seizures finishing. We aim to develop a safe, rapid, non-sedating way to treat seizures using a small amount of carbon dioxide in oxygen. Secondly, inherited problems with transporting sugar from the blood to the brain are increasingly recognised as a cause of epilepsy. We will develop a nation-wide program to identify and treat theseRead moreRead less
Human Epilepsy: Understanding Biology To Improve Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$16,657,948.00
Summary
Our team of neurologists, molecular geneticists, physiologists and brain imaging specialists and leads the world in the discovery of the genetic causes of epilepsy. Through this work we will identify genes underlying epilepsy and study how genetic variations result in the development of seizures. Advanced brain imaging will be used to understand the effects of genetic variation on brain structure and function. This study may lead to new diagnostic methods and treatments for epilepsy.
This is an application for reappointment as a Principal Research Fellow. My primary area of research is preclinical studies of addiction, with a particular emphasis on relapse. I am increasingly engaged in translational studies.
A Potential Analgesic Target In A Novel Clinically-relevant Neuropathic Pain Pathway.
Funder
National Health and Medical Research Council
Funding Amount
$685,811.00
Summary
Persistent pain arising from tissue damage, to nerves, muscles or joints for example, is devastating for patients and a huge social and economic burden. This work will investigate one of the pathways that goes awry after sensory nerves are damaged. These experiments will also test whether a drug being developed to treat Alzheimer's disease is effective at blocking the persistent nerve hypersensitivity that sometimes develops after injury.
Multiple Sclerosis (MS) is an autoimmune disease often diagnosed in early adulthood. Outcomes very enormously, from mild to disabling. This fellowship supports research to improve outcome prediction using genetics and to examine different strategies to optimise treatment outcomes and safety. The main data source is MSBase, which tracks over 31000 people with MS globally and is based in the University of Melbourne's brain Centre at the Royal Melbourne Hospital.
Improving Clinical Translation In Stroke: Targeting Cerebral Oedema In A Large Animal Model
Funder
National Health and Medical Research Council
Funding Amount
$637,530.00
Summary
A common and life-threatening complication of stroke is brain swelling which is the leading cause of death within one week of stroke and a predictor of poor outcome. Current treatments for brain swelling are inadequate. We have developed a drug that blocks the action of the neuropeptide substance P, which is involved in the development of swelling. We will assess the efficacy of this treatment to reduce brain swelling and improve long-term outcome in a relevant pre-clinical model of stroke.